Validation Summary Template for HIV Western Blot Author: Validation Committee Document Number: Equ35-K-02 Effective or Post Date: 4 March 2011.

 

Qualitative Immunoassay Validation Summary Template Author: Validation Committee Document Number: Equ35-H-03 Effective or Post Date: 4 March 2011.

 

Hematology Validation Summary Template Author: Validation Committee Document Number: Equ35-B-02 Effective or Post Date: 23 March 2011 Review.

 

Hematology Validation Summary Template Author: Validation Committee Document Number: Equ35-B-02 Effective or Post Date: 23 March 2011 Review.

 

Auto vs. Manual Differential Validation Summary Template Author: Validation Committee Document Number: Equ35-B-09 Effective or Post Date: 2 March.

 

Qualitative Immunoassay Validation Plan Template Author: Validation Committee Document Number: Equ35-H-02 Effective or Post Date: 4 March 2011.

 

HIV Immunoassay Validation Plan Template Author: Validation Committee Document Number: Equ35-G-02 Effective or Post Date: 4 March 2011 Review.

 

Author: Validation Committee Document Number: Equ35-B-08 Effective or Post Date: 2 March 2010 Review History- Date of last review:.

 

Author: Validation Committee Document Number: Equ35-B-01 Effective or Post Date: 7 June 2010 Review History Date of last review:.

 

Chemistry Validation Plan Template Author: Validation Committee Document Number: Equ35-A-01 Effective or Post Date: Feb 2009 Review History.

 

INFO Title MERGEFORMAT Validation Summary Report Template Document No: INFO Subject MERGEFORMAT Prepared by: INFO Author MERGEFORMAT Author.

 

INFO Title MERGEFORMAT Validation Summary Report Template Document No: INFO Subject MERGEFORMAT Prepared by: INFO Author MERGEFORMAT Author.

 

Author: Validation Committee Document Number: Equ35-G-01 Effective or Post Date: 4 March 2010 Review History Date of last review:.

 

Percentage Minimum detectable difference or absolute Short Term 25 TE Long Term 33 TEWBC±15 1 0. 12x109/L 4 3. 75 5. 0 RBC± 6 1 0. 20x1012/g/L 4 6. 25 8. 33 Neutophils ± 22. 4 2,3 1. 0 x K/uL 7 5. 6 7. 47 Lyytes.

 

020_SMILE Performance Criteria for DAIDS Analytes v. 1. 3. xls 10/13/2010.

 

SMILE Performance Criteria for DAIDS Analytes v. 1. 1 5/1/2009 Percentage Minimum detectable difference or absolute Short Term 25 TE Long Term 33 TE Fibrinogen20.

 

Name of Procedure Smile Guidelines for Icterus Interference Study for Qualitative Assays Guideline Number Equ35-J-03-G Effective Date 6-Oct-09 Subject.

 

Validation Committee Document Number: Equ35-A-04 Effective or Post Date: 19 Dec 2008 Review History Date of last review: 11 Aug 2010 Reviewed.

 

Validation Committee Document Number: Equ35-C-05 Effective or Post Date: 18-June-09 Review History Date of last review: 11 August 2010.

 

SMILE Linearity Author: Validation Committee Document Number: Equ35-A-05 Effective or Post Date: 23-Mar-11 Review History Date of last.

 

Author: Validation Committee Document Number: Equ35-B-05 Effective or Post Date: 23 March 2011 Review History Date of last review:.

 

Name of Procedure Smile Guidelines for Lipemia Interference Study for Qualitative Assays Guideline Number Equ35-J-02-G Effective Date 6-Oct-09 Subject.

 

Validation Committee Document Number: Equ35-A-06 Effective or Post Date: 19 Dec 2008 Review History Date of last review: 11 August 201 Reviewed.

 

Validation Committee Document Number: Equ35-A-07 Effective or Post Date: 19 Dec 2008 Review History Date of last review: 11 August 2010.

 

Validation Committee Document Number: Equ35-A-08 Effective or Post Date: 1-Oct-09 Review History Date of last review: 11 August 2010.

 

Validation Committee Document Number: Equ35-A-03 Effective or Post Date: 19-Dec-2008 Review History Date of last review: 11 Aug 2010 Reviewed.

 

Validation Committee Document Number: Equ35-B-03 Effective or Post Date: 25 Feb 2009 Review History Date of last review: 11 August 2010.

 

Validation Committee Document Number: Equ35-B-04 Effective or Post Date: 25 Feb 09 Review History Date of last review: 11 August 2010 Reviewed.

 

Qualitative Validation Plan Template Author: Validation Committee Document Number: Equ35-08 Effective or Post Date: 4-March 2011 Review.

 

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice Guiding principles 1. Do no harm When introducing changes preserve.

 

Rapid Review Response: Refugees and HIV Prevention Questions: Are refugees at greater risk for HIV and how effective are HIV prevention interventions for refugees The Issue and Why It’s Important.